Leerink Partners Starts Metsera Inc (MTSR) at Outperform

Leerink Partners analyst David Risinger initiates coverage on Metsera Inc (NASDAQ: MTSR) with a Outperform rating and a price target of $77.00.

The analyst comments "We are initiating coverage of MTSR with an Outperform rating and a PT of $77, based upon DCF valuation. Our investment thesis is that the company’s platform and pipeline of novel obesity peptide-based therapeutics offer key advantages relative to competing assets. We believe that Wall Street underappreciates the company’s monthly injectable GLP-1, monthly injectable amylin, daily oral GLP-1 peptide, and peptide manufacturing peptide scale advantages relative to competitors. We would also highlight that the company is led by highly experienced executives with strong track records, including Chairman Clive Meanwell, CEO Whit Bernard, CFO Chris Visioli, CSO Brian Hubbard, and Chief Development Officer Peter Wijngaard."

For an analyst ratings summary and ratings history on Metsera Inc click here. For more ratings news on Metsera Inc click here.

Shares of Metsera Inc closed at $35.10 yesterday.

You May Also Be Interested In

• McGraw Hill (MH) PT Lowered to $19 at BTIG
• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• Arya Resources Announces Successful Phase 2 Drilling at Wedge Lake: Gold and Silver Intersected in All Holes, New Triplet Zone Discovered